now the country may face a fine of millions of euros after its dereliction was referred to the european court of justice (ecj), the guardian reports.
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.
., and bones, and it�s not clear how the drugs will affect them after long-term use.
.
august 2, 2017
.
.